SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering pursuant to NanoString’s existing shelf registration statement. In connection with this offering, NanoString expects to grant the underwriters a 30-day option to purchase up to $7.5 million of additional shares of common stock. NanoString intends to use the net proceeds of the offering for the development and launch of the Company’s Digital Spatial Profiling platform, the continued commercialization of the Company’s portfolio of nCounter-based products, and for general corporate purposes and working capital.

J.P. Morgan and UBS Investment Bank are acting as joint book-running managers for the offering. Baird is acting as lead manager for the offering.

A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on August 30, 2017, amended on September 11, 2017 and declared effective by the SEC on September 14, 2017.  The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.  Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, 25th floor, New York, NY 10019, or by phone at 888-827-7275 or by email at ol-prospectus-request@ubs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contact   
Douglas Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768